SCCA-IgM predicts survival in HCC patients
As reported in the Journal of Gastroenterology & Hepatology, SCCA-IgM levels are elevated in patients with hepatocellular carcinoma (HCC) compared to patients with cirrhosis and healthy controls. Not only does the SCCA-IgM level predict overall and progression-free survival in HCC patients, but the sensitivity of SCCA-IgM in patients with HCC was 2-fold greater than AFP. A decline in SCCA-IgM levels was shown to be associated with response to treatment.
Risk factors for CHC-related death identified
As reported in the World Journal of Gastroenterology, the following risk factors for chronic hepatitis C (CHC)-related deaths have been identified (n=8250 CHC patients; n=144 CHC-related deaths): α-IFN therapy (AOR=0.53); liver cirrhosis (AOR=2.89); hepatocellular carcinoma versus CHC (AOR=8.82); hypertension (AOR=1.76); alcohol consumption (AOR=1.73); and HBsAg positivity (AOR=22.28).
KIT mutations associated with poor prognosis in GISTs
Based on a meta-analysis (18 studies; n=1487) reported in the World Journal of Surgical Oncology, KIT mutations in patients with gastrointestinal stromal tumors (GISTs) are associated with larger tumors (> 5 cm), higher mitotic activity (> 5), more frequent recurrences (OR = 2.06), more frequent metastases (OR = 2.77), and worse 3-year overall survival (OR = 0.47) compared to patients with PDGFRA mutations or wild-type.